Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03161431
Title SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syntrix Biosystems, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.